Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4269/ajtmh.20-0873 http://scihub22266oqcxt.onion/10.4269/ajtmh.20-0873 32828135!7543820!32828135     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Trop+Med+Hyg 2020 ; 103 (4): 1635-1639 Nephropedia Template TP {{tp|p=32828135|t=2020. RETRACTED: Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study |pdf=|usr=}}{{32828135}} gab.com Text RETRACTED: Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study JO: Am J Trop Med Hyg http://www.kidney.de/pget.php?&tw=1&pmid=32828135 #FOAvip RETRACTED ARTICLE: The COVID-19 pandemic is showing an exponential growth, mandating an urgent need to develop an effective treatment. Indeed, to date, a well-established therapy is still lacking. We aimed to evaluate the safety and efficacy of hydroxychloroquine (HCQ) added to standard care in patients with COVID-19. This was a multicenter, randomized controlled trial conducted at three major university hospitals in Egypt. One hundred ninety-four patients with confirmed diagnosis of COVID-19 were included in the study after signing informed consent. They were equally randomized into two arms: 97 patients administrated HCQ plus standard care (HCQ group) and 97 patients administered only standard care as a control arm (control group). The primary endpoints were recovery within 28 days, need for mechanical ventilation, or death. The two groups were matched for age and gender. There was no significant difference between them regarding any of the baseline characteristics or laboratory parameters. Four patients (4.1%) in the HCQ group and 5 (5.2%) patients in the control group needed mechanical ventilation (P = 0.75). The overall mortality did not differ between the two groups, as six patients (6.2%) died in the HCQ group and 5 (5.2%) died in the control group (P = 0.77). Univariate logistic regression analysis showed that HCQ treatment was not significantly associated with decreased mortality in COVID-19 patients. So, adding HCQ to standard care did not add significant benefit, did not decrease the need for ventilation, and did not reduce mortality rates in COVID-19 patients. Twit Text FOAVip RETRACTED: Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study ????Am J Trop Med Hyg http://www.kidney.de/pget.php?&tw=1&pmid=32828135 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32828135 #FOAvip English Wikipedia <ref>{{Cite pmid|32828135}}</ref> RETRACTED: Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study #MMPMID32828135 Abd-Elsalam S; Esmail ES; Khalaf M; Abdo EF; Medhat MA; Abd El Ghafar MS; Ahmed OA; Soliman S; Serangawy GN; Alboraie M Am J Trop Med Hyg 2020[Oct]; 103 (4): 1635-1639 PMID32828135show ga RETRACTED ARTICLE: The COVID-19 pandemic is showing an exponential growth, mandating an urgent need to develop an effective treatment. Indeed, to date, a well-established therapy is still lacking. We aimed to evaluate the safety and efficacy of hydroxychloroquine (HCQ) added to standard care in patients with COVID-19. This was a multicenter, randomized controlled trial conducted at three major university hospitals in Egypt. One hundred ninety-four patients with confirmed diagnosis of COVID-19 were included in the study after signing informed consent. They were equally randomized into two arms: 97 patients administrated HCQ plus standard care (HCQ group) and 97 patients administered only standard care as a control arm (control group). The primary endpoints were recovery within 28 days, need for mechanical ventilation, or death. The two groups were matched for age and gender. There was no significant difference between them regarding any of the baseline characteristics or laboratory parameters. Four patients (4.1%) in the HCQ group and 5 (5.2%) patients in the control group needed mechanical ventilation (P = 0.75). The overall mortality did not differ between the two groups, as six patients (6.2%) died in the HCQ group and 5 (5.2%) died in the control group (P = 0.77). Univariate logistic regression analysis showed that HCQ treatment was not significantly associated with decreased mortality in COVID-19 patients. So, adding HCQ to standard care did not add significant benefit, did not decrease the need for ventilation, and did not reduce mortality rates in COVID-19 patients. |Acetaminophen/therapeutic use[MESH] |Adult[MESH] |Antiviral Agents/*therapeutic use[MESH] |Betacoronavirus/*pathogenicity[MESH] |COVID-19[MESH] |Cephalosporins/therapeutic use[MESH] |Coronavirus Infections/diagnosis/*drug therapy/mortality/virology[MESH] |Drug Administration Schedule[MESH] |Drug Repositioning[MESH] |Egypt[MESH] |Female[MESH] |Humans[MESH] |Hydrocortisone/therapeutic use[MESH] |Hydroxychloroquine/*therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Oseltamivir/therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/*drug therapy/mortality/virology[MESH] |Respiration, Artificial[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH] |Survival Analysis[MESH] |Time Factors[MESH]RETRACTED: Hydroxychloroquine in the Treatment of COVID-19: A Multicen(epmc).pdf DeepDyve Pubget Overpricing